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Background: It is still unclear the actual contribute of dose intensity (DI), dose size (DS) and dose density (DD) in the
conventional chemotherapy of large, B-cell non-Hodgkin lymphomas.
Methods: A prospective, randomized trial compared the cyclic schedule of ProMECE-CytaBOM chemotherapy
(cyc-PC, 6 cycles) with a modified version of it, which administered the same drugs sequentially (seq-PC), with
the same planned cumulative DI and an 83% DD, within the same time frame (113 days), but with three times higher
DS of all the drugs except vincristine.
Results: Fifty-six patients received cyc-PC and 52 seq-PC. The actual mean cumulative DI was 0.79 ± 0.15 with
cyc-PC, 0.78 ± 0.17 with seq-PC. Response was complete in 59% and 52%, partial in 20% and 21%, null in 5%
and 6%, respectively. There were four toxic deaths (two per arm). Relapses occurred in 36% and 37%, respectively.
Toxicity was similar in both arms. Overall, failure-free, progression-free and disease-free survival (median follow-up:
54 months) were statistically indifferent.
Conclusions: The very similar DI actually delivered in both arm seems to be the main common determinant of
the indifferent results recorded. Increasing DS – at least within the limits clinically attainable without stem cell
rescue – does not improve results.
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introduction
Many efforts have been performed to improve the results of
conventional chemotherapy for aggressive non-Hodgkin
lymphomas. However, it is still unclear whether better results
can be achieved by increasing the dose intensity (DI) rather than
the dose size (DS) of the active drugs or by shortening the
schedules of drug administration, thus pursuing a higher dose
density (DD).
The addition of new drugs to those included in the historical
standard regimens (CHOP, BACOP) seemed to strictly comply
with the Goldie and Coldman’s theory [1, 2], according to
which tumor cell kill would benefit by the early exposure to the
highest number of active drugs. However, clinical results of
randomized trials failed to demonstrate clear advantages for the
so-called second- and third-generation chemotherapy regimens
(ProMACE-CytaBOM, m-BACOD, MACOP-B) [3, 4].
Moreover, the comparison of these regimens with CHOP
seemed to question the concept itself of dose intensity that
Hryniuk [5, 6] derived from the basic assumptions of the
Goldie-Coldman model, since the new regimens have a clearly
higher average dose intensity than CHOP (in particular, that
of MACOP-B and ProMACE-CytaBOM is approximately two-
fold higher). It is well-known that some investigators tried to
explain this conceptual failure by advocating the reduction in
cyclophosphamide and doxorubicin—considered as more
active than others—determined by the addition of many other
less active drugs [7].
However, drug DI may be only one of the many variables
potentially able to explain the clinical results of chemotherapy.
The favorable results of high-dose chemotherapy with stem cell
support in many [8, 9]—but not in all—clinical settings of
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non-Hodgkin’s patients should suggest that the amount of dose
(DS) can overcome the multidrug resistance. Actually, the DS of
drugs administered in the most common myeloablative
regimens are 10 to 30 times higher than those given in the
conventional chemotherapy programs, though a contemporary
true increase in their DI is contemporarily achieved. So the
true, individual role of DS and DI in determining therapeutic
results is still to be clarified.
Now, the research for escalated dose in conventional
chemotherapy regimens has become very active, mainly by the
help of growth factor support. While in some trials the increase
of DI has been approached through direct escalation of drug
doses, in others it has been reached through the administration
of standard doses on shortened intervals. In these last cases
a third parameter of chemotherapy is exploited, the so-called
dose density (DD) [10], i.e. the frequency of effective drug dose
administration. This concept complies with the Norton and
Simon’s assumption on tumor heterogeneity [11], according
to which the most efficient therapy should be the most
dose–dense therapy, giving as much drug as possible over as
short a period as possible. Probably, this ideal pattern of
therapy should be better accomplished by sequential than
alternating treatments.
As expected, the design of investigational trials able to test
these chemotherapy parameters separately is not easy in clinical
practice. Here we describe a multicentric, randomized, clinical
experiment in diffuse large B-cell non-Hodgkin’s lymphoma
patients, in which the role of DS was selectively explored under
the same conditions of DI and minimal variation of DD.
patients and methods
eligibility criteria and staging
Between October 1997 and November 2001 112 patients participated in this
multicenter, randomized trial (GISL, LA-04). The following criteria had to
be fulfilled for inclusion into the study: newly diagnosed patients with
diffuse large B-cell lymphoma with exclusion of cases either derived from
previous indolent lymphoma or presenting one of the following variants:
anaplastic, plasmoblastic, T-cell rich B-cell, primary mediastinal B-cell
lymphoma; clinical stage I with bulky mass, stage II with more than three
involved sites or with bulky mass, stage III or IV; age 15–70 years;
performance status (PS) 0–3 according to the European Cooperative
Oncology Group [12]; no serious cardiac, renal, pulmonary and
hepatic co-morbidity; negativity of the serologic test for human
immunodeficiency virus.
Pre-treatment staging procedures included physical examination,
complete blood count, biochemical analyses, bone marrow core biopsy,
chest X-ray and computed tomography scan of chest and abdomen. Initial
bulky disease was defined—in the mediastinum—as lymphoma masses
with maximum width larger than 1/3 of transverse diameter of the thorax
at the level of T5/6, and—outside the mediastinum—as masses with the
largest dimension greater than 10 cm. The prognostic evaluation allowed
by the score of the International Prognostic Index (IPI) [13] was considered
for each patient. Written informed consent was obtained from all
patients before randomization.
After randomization, four patients were excluded for revised histology
(three were defined as high-grade B-cell, Burkitt-like lymphomas, and one as
anaplastic large T-cell lymphoma). So, 108 patients were eligible for the
study, and all are evaluable for the end-points of the study.
treatments
Patients were randomly assigned to receive either six cycles of ProMECE-
CytaBOM chemotherapy or a sequential variant of it which administered
higher doses of the same drugs of the cyclic schedule within the same
time frame.
The cyclic ProMECE-CytaBOM (cyc-PC) was a simple modification of
the original regimen proposed by Fisher et al. [14] in which doxorubicin
(25 mg/m2) was replaced by epidoxorubicin (40 mg/m2). This
epidoxorubicin-based variant had been preferred by the GISL in a previous
randomized trial [15] due to its better effectiveness/toxicity balance.
The sequential variant of the ProMECE-CytaBOM (seq-PC) was
specifically designed to administer single drug doses three times higher
than those delivered in the cyclic schedule, but with total doses of each drug
and total length of the whole treatment fully identical. A GISL pilot study
verified both feasibility and tolerability of a such a schedule [16]. Only
for vincristine the threefold single dose increase was judged potentially
neurotoxic when combined with higher doses of the other antitumoral
agents and its standard dose was repeated no more than four times in the
seq-PC (instead of six times as in the cyc-PC). Oral prednisone
administration paralleled and followed every antitumoral delivery in the seq-
C-P as in the cyc-PC but with a total dose lower (3000 vs. 5040 mg/sqm).
Mesna was given only in the seq-PC, after the two high doses of
cyclophosphamide, while the rescue with folinic acid was provided in both
regimens after methotrexate infusion. The decision to administer growth
factors was left to the experience of each clinician, with the recommendation
of using them strictly on demand, e.g. in case of neutropenia <0.5 · 109/l
(drug dose intensification had not to be pursued in any of the two regimens).
Table 1 details the schedules of both cyc-PC and seq-PC.
Dose intensity was calculated according to the criteria reported by
Hryniuk [5] and to the examples and suggestions offered by de Vita et al.
[17]. Steroids are generally considered of minor importance in relation to
the final clinical outcome of these calculations [17], thus the dose intensity
of prednisone was not taken into account.
Radiotherapy was given after the end of chemotherapy either on those
lymphomatous lesions evaluated as bulky at initial staging or on partially
responsive lesions after chemotherapy. Doses of 36 Gy were recommended
to areas with no signs of disease at the end of chemotherapy and 44 Gy to
sites with partially persisting disease.
response and toxicity
Clinical response was assessed about 1 month after the end of chemotherapy
and after the subsequent radiotherapy, if any. Complete (CR), partial (PR),
null response (NR) and progressive disease (PD) were evaluated according
to the International Workshop criteria [18].
Overall survival (OS) was calculated from the start of therapy to death
from any cause. Failure-free survival (FFS) was measured for all patients
from the start of therapy to the date of treatment failure, disease progression,
relapse or death related to the disease or to the treatment. Relapse-free
survival (RFS) was calculated for complete responders from the end of
treatment to the date of relapse or death from the disease [19].
Toxicity was evaluated according to the standard ECOG grades [12].
statistics
The main endpoint of the study was the 5-year failure-free survival, while
additional endpoints were response rate, 5-year relapse-free survival and
overall survival. Sample size was calculated taking into account that the
study had to be able both to evaluate a possibly more active and toxic
treatment and to pick up a hypothetical advantage, or equivalent, of the
conservative therapy compared. To this aim we chose the formula of
Makuch and Simon [20], which can test the effectiveness of conservative
treatments, too, with the correction of Fleiss [21] for samples of possibly
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unequal size. For these calculations we assumed that a 0.10 difference in
5-year FFS might be probable between the sequential and the cyclic regimen
(0.60 versus 0.50), and chose a two-sided significance level of 0.05 with
a similarly two-sided power of 0.80. Calculations indicated that the whole
sample size should have included 86 evaluable patients, 43 per treatment
arm. Actually, the GISL decided to protract patient accrual and
randomization until the start of a new subsequent protocol, and the
prolonged discussion of the new program allowed 36 additional patients
to be randomized and treated.
Randomization was performed at the GISL Trial Office with
communications by telephone. Patients were stratified on the basis of IPI
score (£1 versus ‡2) and participating center.
results
Of the 108 eligible patients, 56 were randomized to the
treatment with the cyc-PC schedule, 52 with the seq-PC one.
Table 2 reports the main clinical and prognostic characteristics
of the two groups of patients and demonstrates the good
comparability of the two treated groups. The slight, statistically
not significant, prevalence of constitutional symptoms in the
cyc-CP arm is counterbalanced in the seq-PC arm by
a slightly higher proportion of bone marrow involvement
and abnormality of serum albumin concentration,
b2-microglobulin and erythrocyte sedimentation rate.
Both regimens were administered with very similar DI for
each drug, except vincristine which had the planned 1/3
reduction in the sequential schedule (Table 3). The lower DI of
vincristine was counterbalanced by a slight higher one of the
other drugs, so that the average cumulative dose intensity is
nearly superimposable in both regimens (0.79 ± 0.15 with
cyc-PC, 0.78 ± 0.17 with seq-PC). Therefore, the two treatments
can be really considered iso-DI, in spite of the very different DS
of each drug. Granulocyte colony stimulating factors (G-CSF)
were given only when requested either by neutrophil count
below 0.5 · 109/l or by neutropenia even above this limit if
associated with fever or signs of infections. In the seq-PC arm
the mean G-CSF dose was 300 lg/day for 3–4 days after every
drug administration (three cases did not need G-CSF support at
all, seven cases requested G-CSF support for 6 days after some
antitumoral drug administration). In the cyc-PC the use of
G-CSF was only occasional.
Table 1. Doses and schedules of administration of the two regimens
compared, the original cyclic ProMECE-CytaBOM and its sequential
variant
Drugs mg/m2 Route Days
Cyclic P-C
Cyclophosphamide 650 iv 1
Epidoxorubicin 40 iv 1
Etoposide 120 iv 1
Prednisone 60 po 1–14
Cytarabine 300 iv 8
Bleomycin 5 iv 8
Vincristine 1,4 iv 8
Methotrexate 120 iv 8
Folinic acid 10 po 9 (every 6 h for 5 doses)
To be repeated every 21 days for 6 cycles (planned duration 113 days)
Sequential P-C
Cyclophosphamide 1950 iv 1, 64
Mesna 600 iv 1, 64 (h 0 and +6)
Methotrexate 360 iv 15, 78
Folinic acid 20 po 15, 78 (every 6 h
for 5 doses)
Vincristine 1, 4 iv 15, 43, 78, 106
Epidoxorubicin 120 iv 29, 92
Etoposide 360 iv 29, 92
Bleomycin 15 iv 43, 106
Cytarabine 900 iv 50, 113
Prednisone 60 po 1–5, 15–19, 29–33, 43–46,
50–54, 64–68, 78–82,
92–96, 106–109, 113–117.
Planned cumulative relative dose intensity with respect to the cyclic
schedule: 0.95 for all drugs, 1.00 for the six drugs after the exclusion
of vincristine.
Table 2. Clinical characteristics of the 108 eligible patients of the study,
subdivided per treatment arm (per cent in italic)
Characteristics cyc-PC seq-PC Total
Age yrs
Median 56 55 56
Range 26–70 22–68 22–70
Gender
Male 29 52 30 58 59 55
Female 27 48 22 42 49 45
Histologic variants*
Centroblastic 50 89 47 90 97 90
Immunoblastic 6 11 5 10 11 10
Stage
I 9 16 5 10 14 13
II 17 30 14 27 31 29
III 12 22 12 23 24 22
IV 18 32 21 40 39 36
Extranodal involvement
(E stages I–III) 12 21 9 17 21 19
B symptoms 19 34 12 23 31 29
Bulky disease 17 30 17 33 34 31
Bone marrow involvement 14 25 16 31 30 28
Performance status
ECOG
0 38 68 39 75 77 71
1 13 23 7 13 20 18
2 2 4 3 6 5 5
3 3 5 3 6 6 6
IPI score
0–1 28 50 26 50 54 50
2 21 38 22 42 43 40
3 5 9 2 4 7 6
4–5 2 3 2 4 4 4
Alb < 35 g/L 15 27 16 31 31 29
ESR > 50 mm/1st hr 13 23 15 28 28 26
b2-m > 3 mg/L 19 34 22 42 41 38
IPI: International Prognostic Index. Alb: serum albumin concentration.
ESR: erythrocyte sedimentation rate. b2-m: serum b2-microglobulin
concentration.
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Clinical response rate was very similar in both treatment
groups as well as per cent of refractory cases, relapses and death
from any cause as shown in Table 4. In particular, complete
response, progression and relapse rate were 61%, 14 and 25%
in the cyc-PC arm and 58%, 13% and 19% in the seq-PC,
respectively. Among the total number of deaths during the
subsequent follow-up, 20 in the cyc-PC arm and 23 in the
seq-PC one, there was a slight excess of deaths from the disease
in the investigational arm (20 versus 14) and of deaths due to
toxicity or complications in the group with standard therapy.
Thirty-two patients received radiotherapy after
chemotherapy, 18 in the cyc-PC arm, 14 in the seq-PC one.
Response rate did not differ in the two treatment groups related
to administration of local RT according to the criteria adopted.
Median follow-up for the whole population of the study
was 46 months (range 2–81), 54 months for patients alive (range
24–81). Projected 5-year FFS, RFS and OS show slight and
statistically not significant differences between treatments
(Figure 1), though with a constant slight advantage in favor
of the cyc-PC arm (FFS: 44 versus 34%; RFS: 75 versus 65%;
OS: 63 versus. 53%). No substantial differences of FFS, RFS and
OS were found between patients with favorable (IPI 0–1) and
unfavorable (IPI ‡2) prognostic score of the two treatment
arms.
Toxicity was moderate in both groups of patients (see
Table 5). Four patients, two per arm, died of infections or septic
shock during chemotherapy despite a powerful antibiotic and
G-CSF therapy. Hematologic toxicity was comparable as far
as anemia and thrombocytopenia are concerned, while
neutropenia was more frequent and heavy with seq-PC.
Nonhematologic toxicity was mainly related to reactivation of
HBV infections in the liver at the end of chemotherapy
Table 3. Planned and actually delivered dose intensity (DI) of each
drug in the 108 patients treated with one of the two ProMECE-CytaBOM
regimens. Calculations were made in relation to the doses of
the cyclic regimen, taken as reference schedule
Planned DI Delivered DI
Drugs cyc-PC seq-PC cyc-PC seq-PC
Cyclophosphamide 1 1 0.8260.17 0.8460.19
Epidoxorubicin 1 1 0.7860.14 0.8260.19
Etoposide 1 1 0.8260.15 0.8060.22
Cytarabine 1 1 0.8360.17 0.8560.12
Bleomycin 1 1 0.8260.20 0.8360.14
Vincristine 1 0.67 0.6660.16 0.4960.11
Methotrexate 1 1 0.8360.16 0.8260.18
Mean 1 0.95 0.7960.15 0.7860.17
Table 4. Clinical response to and evolution after Cyc-P-C and
Seq-P-C regimens
cyc-PC seq-PC Total
No. % No. % No. %
Complete response 34 61 30 58 64 59
Partial response 11 20 12 23 23 21
Null response 3 5 3 6 6 6
Progression 8 14 7 13 15 14
Relapse 12 21 10 19 22 20
Death from disease 14 25 19 36 33 31
Death from toxicity
or complications
6 11 4 8 9 9
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Figure 1. Overall survival, failure-free survival and disease-free survival
recorded in the 56 patients treated with the original, cyclic ProMECE-
CytaBOM schedule (cyc-PC) and in the 52 treated with the sequential
modification of the same regimen (seq-PC), administering three-fold
higher drug dose sizes, with equivalent cumulative dose intensity.
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(two grade four cases, one per arm) or to transient increased
serum creatinine and urea concentration (one case, treated
with cyc-PC), probably due to insufficient liquid infusion.
Mucosytis was more frequent in the seq-PC arm.
discussion
The therapeutic efficacy of conventional therapy is still
unsatisfactory for patients with large B-cell non Hodgkin’s
lymphoma and new strategies are warranted in this clinical
setting. The administration of high-dose chemotherapy with
autologous stem-cell transplantation has been the main major
clinical progress since the introduction of CHOP about 30 years
ago. Even though its use in first-line patients remains
controversial, the large amount of results obtained as
second-line therapy contributed to strengthen the hypothesis
that a high dose of an antitumoral drug is better than
a standard one. Possible explanations of higher effectiveness of
increasing doses might be (a) prolonged exposure time to
greater than a cytotoxic threshold, (b) penetration of sanctuary
sites, (c) producing cytotoxicity through alternative
mechanisms. More probably high-doses can more successfully
interfere with the active processes of either extracellular
extrusion of the drug or sequestration of it into the cytoplasm,
away from the nuclear targets, that characterize the multidrug
resistance. As a matter of fact, the idea that increasing drug
DI can be a reliable way to improve clinical outcome has been
prevalent in clinical studies with conventional chemotherapy.
Now, however, it is still unproven whether it is more useful to
simply escalate drug doses administered at the standard time
intervals or to shorten the time intervals while maintaining the
DS unmodified, or even to pursue both aims simultaneously.
Many modifications of the current chemotherapy schedules
have been proposed to simultaneously increase DS and DI or
this last and DD. The purpose of the present study was to
explore the actual contribute of DS in the therapy of large B-cell
lymphomas in an experimental condition with equal DI and as
similar DD as possible. This would be a clinical test, without
confounding effects of time, of the Goldie and Coldman’s model
[1], which predicts an inverse relationship between DS and
development of drug resistance, The results can help to correctly
direct the next clinical efforts towards either dose escalation or
time shortening (or both).
The choice of ProMECE-CytaBOM as test bench for
investigational schedule manipulations is simply justified by
the fact that all the GISL centers were very familiar with this
third-generation regimen [15, 22, 23]. This was the only
reason why it was preferred to CHOP which was developed
more than 30 years ago [24] and is still considered a very
effective conventional treatment for aggressive lymphomas
and a simple experimental tool for clinical investigation [25].
Our results indicate that in two prognostically comparable
subsets of patients with large B-cell lymphoma two iso-DI
regimens, one of which with drug threefold higher doses,
have very similar rates of response, relapse, specific death and
toxic death. Actually, FFS, RFS and OS curves do not show
statistically significant differences. The slightly higher
hematological toxicity observed with the regimen delivering
escalated doses can be considered to have been partially
mitigated by the larger use of growth factors. Thus, a first
level of conclusion should be that DI is the truly important
parameter in the treatment of lymphomas and that the
increase of DS or of the number of drugs administered
are not sufficient devices to give appreciable clinical results.
A comparison with the findings from other clinical
experiments testing modifications of doses and time of drug
administration in lymphoma therapy can be made with a few
studies mainly dealing with CHOP.
The Southwest Oncology Group (SWOG) [26] reported on
cohort of 88 intermediate- or high-grade lymphoma patients
treated with a 2 week CHOP schedule in which
cyclophosphamide was given at a dose of 1600 mg/m2 and
doxorubicin at a dose of 65 mg/sqm. The study demonstrated
the feasibility of such intensification and, though the 2-year
progression-free survival was lower than expected (51% versus
60%), the estimated overall survival at 5 years was 14% better
than that of patients treated with standard CHOP in an
earlier SWOG study. In this trial a clear-cut intensification
was reached through both escalating doses and shortening
intervals among cycles.
The Japan Clinical Oncology Group [27] conducted an
interesting randomized trial in aggressive lymphoma patients.
Thirty-two patients were assigned to receive eight cycles of
standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin
50 mg/m2, vincristine 1.4 mg/m2 and prednisone 100 mg for
5 days) every two weeks or six cycles of dose-escalated CHOP
(cyclophosphamide 1500 mg/m2, doxorubicin 70 mg/m2,
vincristine 1.4 mg/m2 and prednisone 100 mg for 5 days)
every 3 weeks. Hematological toxicity was higher in the
escalated-dose arm, despite the prophylactic use of
lenograstim, but response rate and progression-free survival
were lower. This trial tested the efficacy of a 150% dose
densification (in this case corresponding also to 150% dose
intensification) versus a dose escalation of 200% for
cyclophosphamide and 140% of doxorubicin (with a 147%
mean cumulative intensification). According to this trial,
under condition of nearly equal mean dose intensity
(150 versus 147%), administrating standard doses with
higher frequency was more effective than escalating doses
at standard intervals.
Balzarotti et al. [28] reported very promising results
(74% complete remission rate) with a modified biweekly
CHOP—both dose-intense and dose-dense—escalating the
dose of cyclophosphamide and doxorubicin at 1750 and
Table 5. Number of patients of both treatment arms in whom severe
toxicity grades were recorded (ECOG grades 3 and 4)
cyc-PC seq-PC
Grades Grades
3 4 3 4
Hemoglobin 1 2 2 0
Neutrophils 7 6 11 9
Platelets 0 1 2 0
Liver function tests 1 1 2 1
Renal function tests 0 1 0 0
Mucosytis 2 0 3 1
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75 mg/m2, respectively. In this study, dose escalation was 233%
for cyclophosphamide and 150% for doxorubicin, and dose
densification was, again, 150%, with a resulting average dose
intensification for the whole regimen of 240%.
Another very instructive study was performed by the
German High-Grade Non-Hodgkin’s Lymphoma Study
Group separately in patients younger than 60 [29] and in those
older than 61 years of age [30]. In both trials three treatments
were compared to standard CHOP (CHOP 21), a biweekly
(CHOP 14), an etoposide added CHOP at standard intervals
(CHOEP 21) and a biweekly version of this last (CHOEP 14).
Among young patients, and in comparison with CHOP 21,
CHOP 14 was significantly better only with respect to 5-year
overall survival, CHOEP 21 improved 5-year event-free survival
only, whereas CHOEP 14 significantly increased complete
response rate, reduced disease progression under therapy and
improved both overall and event-free survival. CHOP 14 was
also more toxic and required obligatory use of growth factors. In
older patients cycle shortening (CHOP 14) had a more favorable
impact on complete response rate, 5-year time to treatment
failure, and 5-year overall survival, than did the inclusion of
etoposide. Attempting both cycle shortening and etoposide
addition (CHOEP 14) markedly reduced dose intensity (83%
versus > 93% of the other regimens) and led to the relatively
poorest clinical results. The message should be that dose
densification is a practicable and effective way to increase the
performances of chemotherapy, whereas the addition of a new
drug, such as etoposide, can further increase efficacy but with
a raise of toxicity that can be intolerable by frail and elder
patients and detrimental to the clinical outcome. These results
seem to disagree with those of Fisher et al. [4] who failed to
demonstrate any advantage over CHOP for three regimens
(m-BACOD, ProMACE-Cyta-BOM and MACOP-B) that
have to be considered as actually intensified, densified and
enriched with one or more drugs with respect to CHOP
(specifically also with etoposide in the case of ProMACE-
CytaBOM).
However, taking clear lessons from these clinical experiences
is difficult since we are still using imperfect clinical tools, and
are able to only partially explain what happens in the treatment
of our patients. The assumptions which are inherent in the
basic concepts of DI, DS and DD probably represent an
oversimplication of the biological reality (i.e. the equivalent
activity of empirically defined ‘standard’ doses of different
drugs, the expected proportionality of cell killing activity of
a drug to the dose administered). We need to take into account
further information on individual drug activity, such as the
actual synergism existing among chemotherapeutic agents
(and among these and radiotherapy), the role of scheduled time
and sequence of administration of drugs, the area under the
concentration-time curve of each drugs.
At present, from the results of both this study and some
recent others it appears that speeding up the sequence of
administration of the drugs of a current and effective
chemotherapy regimen is the most simple and safe way to
increase DI and to improve clinical results in large, B-cell
lymphoma patients. This conclusion seems to be consistent with
that drawn by the Norton and Simon’s theory on heterogenous
tumor cells with different growth speed [31]. Within the wide
range of doses which can be delivered now with support of
growth factors—but without stem-cell rescue—the increase of
DI through an increase of DS can variably improve effectiveness
sometimes, but it constantly raises toxicity, often with an
opposite effect on survival. In both cases the prophylactic use of
growth factors is needed.
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